MCID: PRG009
MIFTS: 50

Progressive Multifocal Leukoencephalopathy

Categories: Rare diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Progressive Multifocal Leukoencephalopathy

MalaCards integrated aliases for Progressive Multifocal Leukoencephalopathy:

Name: Progressive Multifocal Leukoencephalopathy 12 50 51 56 14
Leukoencephalopathy, Progressive Multifocal 50 42 69
Pml 12 50 56
Leukoencephalopathy Progressive Multifocal 52
Progressive Multifocal Leukoencephalitis 56

Characteristics:

Orphanet epidemiological data:

56
progressive multifocal leukoencephalopathy
Inheritance: Not applicable; Age of onset: All ages;

Classifications:



External Ids:

Disease Ontology 12 DOID:643
ICD10 33 A81.2
ICD9CM 35 046.3
MeSH 42 D007968
NCIt 47 C26815
SNOMED-CT 64 22255007
Orphanet 56 ORPHA217260
MESH via Orphanet 43 D007968
UMLS via Orphanet 70 C0023524
ICD10 via Orphanet 34 A81.2
UMLS 69 C0023524

Summaries for Progressive Multifocal Leukoencephalopathy

NINDS : 51 Progressive multifocal leukoencephalopathy (PML) is a disease of the white matter of the brain, caused by a virus infection that targets cells that make myelin--the material that insulates nerve cells (neurons).  Polyomavirus JC (often called JC virus) is carried by a majority of people and is harmless except among those with lowered immune defenses.  The disease is rare and occurs in patients undergoing chronic corticosteroid or immunosuppressive therapy for organ transplant, or individuals with cancer (such as Hodgkin’s disease or lymphoma).  Individuals with autoimmune conditions such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosis -- some of whom are treated with biological therapies that allow JC virus reactivation -- are at risk for PML as well.  PML is most common among individuals with HIV-1 infection / acquired immune deficiency syndrome (AIDS).  Studies estimate that prior to effective antiretroviral therapy, as many as 5 percent of persons infected with HIV-1 eventually develop PML that is an AIDS-defining illness.  However, current HIV therapy using antiretroviral drugs (ART), which effectively restores immune system function, allows as many as half of all HIV-PML patients to survive, although they may sometimes have an inflammatory reaction in the regions of the brain affected by PML.  The symptoms of PML are diverse, since they are related to the location and amount of damage in the brain, and may evolve over the course of several weeks to months  The most prominent symptoms are clumsiness; progressive weakness; and visual, speech, and sometimes personality changes.  The progression of deficits leads to life-threatening disability and (frequently) death.  A diagnosis of PML can be made following brain biopsy or by combining observations of a progressive course of the disease, consistent white matter lesions visible on a magnetic resonance imaging (MRI) scan, and the detection of the JC virus in spinal fluid.

MalaCards based summary : Progressive Multifocal Leukoencephalopathy, also known as leukoencephalopathy, progressive multifocal, is related to lymphoma and systemic lupus erythematosus. An important gene associated with Progressive Multifocal Leukoencephalopathy is ITGA4 (Integrin Subunit Alpha 4), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Natalizumab and Interferon beta-1b have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and liver, and related phenotypes are cellular and cardiovascular system

Disease Ontology : 12 A viral infectious disease that involves reactivation of JC polyomavirus in immune-compromised individuals which causes the loss of white matter (which is made up of myelin, a substance the surrounds and protects nerve fibers) in multiple areas of the brain. The symptoms include hemiparesis, aphasia, dysarthria, hemianopia, cognitive impairment and coma.

NIH Rare Diseases : 50 progressive multifocal leukoencephalopathy (pml) is a neurological disorder that damages the myelin that covers and protects nerves in the white matter of the brain. it is caused by the jc virus (jcv). by age 10, most people have been infected with this virus, but it rarely causes symptoms unless the immune system becomes severely weakened. the disease occurs, rarely, in organ transplant patients; people undergoing chronic corticosteroid or immunosuppressive therapy; and individuals with cancer, such as hodgkin’s disease, lymphoma, and sarcoidosis.  pml is most common among individuals with acquired immune deficiency syndrome (aids). last updated: 4/1/2011

Wikipedia : 72 Progressive multifocal leukoencephalopathy (PML) is a rare and usually fatal viral disease characterized... more...

Related Diseases for Progressive Multifocal Leukoencephalopathy

Diseases related to Progressive Multifocal Leukoencephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 172)
id Related Disease Score Top Affiliating Genes
1 lymphoma 31.0 CD40LG IL2 TNF
2 systemic lupus erythematosus 29.5 CD40LG IL2 PDCD1 TNF
3 leukemia, acute promyelocytic, somatic 12.1
4 acute promyelocytic leukemia pml/rara type 12.1
5 aids - neurological complications 11.0
6 scirrhous adenocarcinoma 10.7 IL2 TNF
7 autoimmune polyglandular syndrome type 3 10.6 IL2 TNF
8 moved to 244450 10.6 ITGA4 TNF
9 spirillary rat-bite fever 10.6 IL2 TNF
10 hemangioma of orbit 10.6 IL2 TNF
11 rickettsialpox 10.6 CD40LG TNF
12 lung disease 10.6 CD40LG TNF
13 submandibular gland disease 10.6 CD40LG TNF
14 plantar wart 10.6 IL2 TNF
15 amyotrophic lateral sclerosis type 10 10.5 IL2 TNF
16 japanese encephalitis 10.5 CD40LG IL2
17 lymphocytic colitis 10.5 IL2 TNF
18 spoan syndrome 10.5 CD40LG STAT1
19 tinea favosa 10.5 IL2 TNF
20 uveitis 10.5 CD40LG TNF
21 agammaglobulinemia, microcephaly, and severe dermatitis 10.5 CD40LG IL2
22 hyperthyroxinemia 10.5 HTR2A MECP2
23 cd40 ligand deficiency 10.5 CD40LG STAT1
24 gonococcal synovitis 10.5 CD40LG STAT1
25 central nervous system leiomyosarcoma 10.5 CD40LG TNF
26 indolent myeloma 10.5 CD40LG TNF
27 parametritis 10.5 IL2 TNF
28 ileocolitis 10.5 CD40LG TNF
29 variola major 10.4 CD40LG MBP
30 dermatomycosis 10.4 CD40LG TNF
31 chronic duodenal ileus 10.4 CD40LG MBP
32 gestational diabetes 10.4 CD40LG MBP
33 alkhurma hemorrhagic fever 10.4 CD40LG TNF
34 epileptic encephalopathy, early infantile, 33 10.4 CD40LG RAG1
35 temporal arteritis 10.3 CD40LG MBP
36 tularemia 10.3 CD40LG IL2 TNF
37 foodborne botulism 10.3 CD40LG IL2 TNF
38 membranoproliferative glomerulonephritis 10.3 CD40LG IL2 TNF
39 early congenital syphilis 10.3 CD40LG IL2 TNF
40 endogenous depression 10.3 CD40LG IL2 TNF
41 esophagus melanoma 10.3 CD40LG IL2 TNF
42 benign mammary dysplasia 10.3 CD40LG IL2 TNF
43 vulvar sarcoma 10.3 CD40LG MBP
44 heart sarcoma 10.3 CD40LG IL2 TNF
45 acute interstitial pneumonia 10.3 CD40LG IL2 TNF
46 leukemia 10.3
47 opportunistic bacterial infectious disease 10.3 CD40LG IL2 TNF
48 mesenchymal cell neoplasm 10.3 CD40LG IL2 TNF
49 discitis 10.3 CD40LG TNF
50 uterus interstitial leiomyoma 10.3 CD40LG IL2 TNF

Graphical network of the top 20 diseases related to Progressive Multifocal Leukoencephalopathy:



Diseases related to Progressive Multifocal Leukoencephalopathy

Symptoms & Phenotypes for Progressive Multifocal Leukoencephalopathy

MGI Mouse Phenotypes related to Progressive Multifocal Leukoencephalopathy:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 IGHMBP2 IL2 ITGA4 MBP MECP2 PDCD1
2 cardiovascular system MP:0005385 10.19 CD40LG IGHMBP2 IL2 ITGA4 MECP2 PDCD1
3 behavior/neurological MP:0005386 10.15 MECP2 RAG1 STAT1 TNF HTR2A IGHMBP2
4 homeostasis/metabolism MP:0005376 10.11 CD40LG IGHMBP2 IL2 MBP MECP2 PDCD1
5 endocrine/exocrine gland MP:0005379 10.1 CD40LG HTR2A IL2 MECP2 PDCD1 RAG1
6 immune system MP:0005387 10.09 MBP MECP2 PDCD1 RAG1 STAT1 TNF
7 hematopoietic system MP:0005397 10.08 CD40LG IL2 ITGA4 MBP PDCD1 RAG1
8 mortality/aging MP:0010768 10.07 CD40LG IGHMBP2 IL2 ITGA4 MBP MECP2
9 digestive/alimentary MP:0005381 9.99 HTR2A IGHMBP2 IL2 RAG1 STAT1 TNF
10 liver/biliary system MP:0005370 9.88 IL2 MECP2 PDCD1 RAG1 STAT1 TNF
11 nervous system MP:0003631 9.86 CD40LG IGHMBP2 MBP MECP2 PDCD1 RAG1
12 neoplasm MP:0002006 9.72 PDCD1 RAG1 STAT1 TNF IL2
13 respiratory system MP:0005388 9.63 PDCD1 RAG1 TNF IGHMBP2 IL2 MECP2
14 skeleton MP:0005390 9.5 CD40LG HTR2A MECP2 PDCD1 RAG1 STAT1
15 vision/eye MP:0005391 9.17 IL2 MBP MECP2 PDCD1 RAG1 STAT1

Drugs & Therapeutics for Progressive Multifocal Leukoencephalopathy

Drugs for Progressive Multifocal Leukoencephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Natalizumab Approved, Investigational Phase 4 189261-10-7
2
Interferon beta-1b Approved Phase 4 145155-23-3
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5 Gastrointestinal Agents Phase 4,Phase 2
6 Immunosuppressive Agents Phase 4,Phase 2
7 Adjuvants, Immunologic Phase 4
8 Anti-Infective Agents Phase 4,Phase 2,Phase 1
9 Antiviral Agents Phase 4,Phase 2
10 Interferon-beta Phase 4
11 interferons Phase 4
12 Antiemetics Phase 4
13 Anti-Inflammatory Agents Phase 4
14 Antineoplastic Agents, Hormonal Phase 4
15 Autonomic Agents Phase 4
16 Fingolimod Hydrochloride Phase 4
17 glucocorticoids Phase 4
18 Hormone Antagonists Phase 4
19 Hormones Phase 4
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
21 Methylprednisolone acetate Phase 4
22 Methylprednisolone Hemisuccinate Phase 4
23 Neuroprotective Agents Phase 4
24 Peripheral Nervous System Agents Phase 4
25 Prednisolone acetate Phase 4
26 Prednisolone hemisuccinate Phase 4
27 Prednisolone phosphate Phase 4
28 Protective Agents Phase 4
29
Emtricitabine Approved, Investigational Phase 2 143491-57-0 60877
30
Enfuvirtide Approved, Investigational Phase 2 159519-65-0 16130199
31
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
32
Didanosine Approved Phase 2 69655-05-6 50599
33
Lenograstim Approved Phase 2 135968-09-1
34
Zalcitabine Approved Phase 2 7481-89-2 24066
35
Zidovudine Approved Phase 2 30516-87-1 35370
36
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
37 Vedolizumab Approved Phase 2 943609-66-3
38
Mefloquine Approved Phase 1, Phase 2 53230-10-7 4046
39
rituximab Approved Phase 2 174722-31-7 10201696
40 Anti-HIV Agents Phase 2
41 Anti-Retroviral Agents Phase 2
42 Nucleic Acid Synthesis Inhibitors Phase 2
43 Reverse Transcriptase Inhibitors Phase 2
44
Tenofovir Phase 2 147127-20-6 464205
45 Antimetabolites Phase 2
46 Antimetabolites, Antineoplastic Phase 2
47 topoisomerase I inhibitors Phase 2
48 Topoisomerase Inhibitors Phase 2
49 Antibodies Phase 1, Phase 2
50 Immunoglobulins Phase 1, Phase 2

Interventional clinical trials:

(show all 28)

id Name Status NCT ID Phase Drugs
1 Methylprednisolone During the Switch Between Natalizumab and Fingolimod Recruiting NCT02769689 Phase 4 Methylprednisolone;Placebo;natalizumab (NTZ);fingolimob (FTY)
2 Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide Active, not recruiting NCT01970410 Phase 4 teriflunomide
3 Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) Terminated NCT01211665 Phase 4 Methylprednisolone;Prednisolone
4 Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis Terminated NCT01701856 Phase 4 Interferon beta-1b
5 Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies Recruiting NCT02118584 Phase 3 Etrolizumab
6 Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125) Completed NCT00120367 Phase 2 Enfuvirtide;Tenofovir-Emtricitabine
7 Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients Completed NCT00001048 Phase 2 Filgrastim;Cytarabine;Zidovudine;Zalcitabine;Didanosine
8 Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML) Completed NCT00002395 Phase 2 Topotecan
9 Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease Completed NCT00619489 Phase 2 vedolizumab
10 Brentuximab Vedotin for Systemic Sclerosis Recruiting NCT03222492 Phase 1, Phase 2
11 Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) Terminated NCT00746941 Phase 1, Phase 2 mefloquine
12 Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403 Terminated NCT00655824 Phase 2 ofatumumab
13 A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection Completed NCT00002270 Interferon alfa-2b;Zidovudine
14 Retrospective Study of the Survival of Patients Suffering From Hiv-related Progressive Multifocal Leukoencephalopathy Completed NCT02895581
15 A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients Completed NCT00000945 Cidofovir;Probenecid
16 Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome Completed NCT00342602
17 JC Virus Reactivation in Multiple Sclerosis Completed NCT02004444
18 A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine Completed NCT00002274 Didanosine
19 JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab Completed NCT01070836 natalizumab
20 Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort Completed NCT01070719
21 Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control Completed NCT01626248
22 Drug Exposure Registry for GSK2248761, an Investigational NNRTI Completed NCT01458132 GSK2248761
23 Natural History Study of Progressive Multifocal Leukoencephalopathy (PML) Recruiting NCT01730131
24 Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells Recruiting NCT02694783 Early Phase 1
25 Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis Recruiting NCT01981161
26 Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML) Active, not recruiting NCT01132053
27 Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant Active, not recruiting NCT01386359 No Intervention
28 Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy Terminated NCT01211639

Search NIH Clinical Center for Progressive Multifocal Leukoencephalopathy

Cochrane evidence based reviews: leukoencephalopathy, progressive multifocal

Genetic Tests for Progressive Multifocal Leukoencephalopathy

Anatomical Context for Progressive Multifocal Leukoencephalopathy

MalaCards organs/tissues related to Progressive Multifocal Leukoencephalopathy:

39
Brain, T Cells, Liver, Kidney, Lung, B Cells, Testes

Publications for Progressive Multifocal Leukoencephalopathy

Articles related to Progressive Multifocal Leukoencephalopathy:

(show top 50) (show all 657)
id Title Authors Year
1
Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies. ( 28913726 )
2017
2
Progressive multifocal leukoencephalopathy 11A years after liver transplantation: a case report. ( 28900866 )
2017
3
Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? ( 28681343 )
2017
4
Insight into Metabolic (1)H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions. ( 28928709 )
2017
5
Late onset progressive multifocal leukoencephalopathy in Hodgkin lymphoma. ( 28526178 )
2017
6
Progressive multifocal leukoencephalopathy in a patient with lymphoma and presumptive hyper IgE syndrome. ( 28643229 )
2017
7
Refractory T-Cell Anergy and Rapidly Fatal Progressive Multifocal Leukoencephalopathy After Prolonged CTLA4 Therapy. ( 28638849 )
2017
8
The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management. ( 27890176 )
2017
9
Corrigendum to "Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?" [J. Neurol. Sci. 378 (2017) 233-237]. ( 28870565 )
2017
10
Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy. ( 28791614 )
2017
11
Progressive multifocal leukoencephalopathy in a 44-year old male with idiopathic CD4+ T-lymphocytopenia treated with mirtazapine and mefloquine. ( 28879898 )
2017
12
JC Virus-Related Progressive Multifocal Leukoencephalopathy After Living-Donor Liver Transplant: A Rare Case. ( 28800720 )
2017
13
Progressive multifocal leukoencephalopathy in an immunocompetent patient. ( 28863831 )
2017
14
Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study. ( 28674518 )
2017
15
Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. ( 28681388 )
2017
16
Low-signal Intensity Rims along the Cerebral Cortex and U-fibers on Susceptibility-weighted Imaging in Progressive Multifocal Leukoencephalopathy. ( 28592708 )
2017
17
Cerebellar Involvement in an Immunocompetent Patient Presenting with Progressive Multifocal Leukoencephalopathy. ( 28912987 )
2017
18
Evaluation of RAG1 mutations in an adult with combined immunodeficiency and progressive multifocal leukoencephalopathy. ( 28216420 )
2017
19
Progressive Multifocal Leukoencephalopathy: Endemic Viruses and Lethal Brain Disease. ( 28637388 )
2017
20
A role for susceptibility weighted imaging in progressive multifocal leukoencephalopathy. ( 28665088 )
2017
21
Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. ( 28836899 )
2017
22
Deep-Sequence Identification and Role in Virus Replication of a JC Virus Quasispecies in Patients with Progressive Multifocal Leukoencephalopathy. ( 27795410 )
2017
23
A prominent lactate peak as a potential key magnetic resonance spectroscopy (MRS) feature of progressive multifocal leukoencephalopathy (PML): Spectrum pattern observed in three patients. ( 28623673 )
2017
24
CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. ( 27815407 )
2016
25
Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals. ( 27686675 )
2016
26
Extrapyramidal syndrome with generalized chorea as an atypical presentation of progressive multifocal leukoencephalopathy. ( 26968822 )
2016
27
Rehabilitation outcome of progressive multifocal leukoencephalopathy in HIV-positive patients: a report of two cases. ( 27539012 )
2016
28
A case of progressive multifocal leukoencephalopathy with Takayasu arteritis and indolent adult T-cell lymphoma/leukemia. ( 26797479 )
2016
29
Progressive Multifocal Leukoencephalopathy in a Lung Transplant Recipient: Isolation of John Cunningham (JC) Virus from Bronchoalveolar Lavage. ( 27013844 )
2016
30
Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. ( 27401179 )
2016
31
Progressive multifocal leukoencephalopathy with bilateral middle cerebellar peduncle lesions confirmed by repeated CSF-JC virus tests and coexistence of JC virus granule cell neuronopathy. Report of a case. ( 27356732 )
2016
32
Progressive multifocal leukoencephalopathy masquerading as cerebellar infarction. ( 27056083 )
2016
33
Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks. ( 28039520 )
2016
34
Low-signal-intensity rim on susceptibility-weighted imaging is not a specific finding to progressive multifocal leukoencephalopathy. ( 26944139 )
2016
35
Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy. ( 27600113 )
2016
36
Progressive Multifocal Leukoencephalopathy with Balanced CD4/CD8 T-Cell Infiltration and Good Response to Mefloquine Treatment. ( 27301518 )
2016
37
Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. ( 27273076 )
2016
38
Cidofovir for treatment of progressive multifocal leukoencephalopathy in a newly diagnosed sarcoidosis patient - a valid therapeutic option? ( 26944175 )
2016
39
Progressive Multifocal Leukoencephalopathy Localized in the Cerebellum and Brainstem Associated with Idiopathic CD4(+) T Lymphocytopenia. ( 27301521 )
2016
40
Primary cerebellar progressive multifocal leukoencephalopathy (PML) shows increased accumulation in (123)I-IMP SPECT. ( 26810523 )
2016
41
Progressive multifocal leukoencephalopathy after autologous peripheral blood stem cell transplantation in a patient with multiple myeloma treated with combination therapy. ( 27538654 )
2016
42
Progressive multifocal leukoencephalopathy secondary to rituximab-induced immunosuppression and the presence of John Cunningham virus: a case report and literature review. ( 27594961 )
2016
43
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. ( 27456945 )
2016
44
Rituximab-Associated Inflammatory Progressive Multifocal Leukoencephalopathy. ( 27965904 )
2016
45
Progressive Multifocal Leukoencephalopathy and Systemic Lupus Erythematosus: Focus on Etiology. ( 27065427 )
2016
46
Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk. ( 27554031 )
2016
47
Diagnostic delay in progressive multifocal leukoencephalopathy. ( 27231708 )
2016
48
Recurrence of progressive multifocal leukoencephalopathy despite immune recovery in two HIV seropositive individuals. ( 26727910 )
2016
49
Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry. ( 27997580 )
2016
50
JC Polyomavirus Abundance and Distribution in Progressive Multifocal Leukoencephalopathy (PML) Brain Tissue Implicates Myelin Sheath in Intracerebral Dissemination of Infection. ( 27191595 )
2016

Variations for Progressive Multifocal Leukoencephalopathy

Expression for Progressive Multifocal Leukoencephalopathy

Search GEO for disease gene expression data for Progressive Multifocal Leukoencephalopathy.

Pathways for Progressive Multifocal Leukoencephalopathy

Pathways related to Progressive Multifocal Leukoencephalopathy according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.06 CD40LG IL2 RAG1 RPS27A STAT1 TNF
2
Show member pathways
12.4 CD40LG IL2 ITGA4 STAT1 TNF
3
Show member pathways
12.08 CD40LG IL2 PDCD1 TNF
4 11.94 HTR2A MECP2 TNF
5
Show member pathways
11.91 IL2 STAT1 TNF
6 11.87 CD40LG ITGA4 PDCD1
7
Show member pathways
11.78 IL2 ITGA4 STAT1
8 11.75 IL2 MBP TNF
9
Show member pathways
11.73 CD40LG ITGA4 STAT1 TNF
10
Show member pathways
11.66 IL2 STAT1 TNF
11 11.6 CD40LG IL2 PDCD1 RAG1 STAT1 TNF
12 11.51 IL2 ITGA4 TNF
13
Show member pathways
11.46 CD40LG IL2 TNF
14
Show member pathways
11.3 CD40LG IL2 TNF
15 11.1 CD40LG ITGA4 PDCD1 TNF
16 11.04 IL2 TNF
17 10.96 CD40LG IL2 TNF

GO Terms for Progressive Multifocal Leukoencephalopathy

Biological processes related to Progressive Multifocal Leukoencephalopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.78 CD40LG IL2 PDCD1 RPS27A
2 MAPK cascade GO:0000165 9.62 IL2 MBP RPS27A TNF
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.61 CD40LG RPS27A TNF
4 leukocyte cell-cell adhesion GO:0007159 9.46 CD40LG ITGA4
5 B cell differentiation GO:0030183 9.43 CD40LG ITGA4 RAG1
6 positive regulation of T cell differentiation GO:0045582 9.4 IL2 RAG1
7 leukocyte tethering or rolling GO:0050901 9.37 ITGA4 TNF
8 immune response GO:0006955 9.35 CD40LG IL2 MBP RAG1 TNF
9 regulation of immunoglobulin secretion GO:0051023 9.16 CD40LG TNF
10 tumor necrosis factor-mediated signaling pathway GO:0033209 8.92 CD40LG RPS27A STAT1 TNF

Molecular functions related to Progressive Multifocal Leukoencephalopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 8.8 CD40LG STAT1 TNF

Sources for Progressive Multifocal Leukoencephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....